<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA) is a life-threatening <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> disorder that can be treated with bone marrow transplantation, immunosuppressive therapy, and high-dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we report long-term follow-up on 67 SAA patients (44 treatment-naive and 23 refractory) treated with high-dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>At 10 years, the overall actuarial survival was 88%, the response rate was 71% with the majority being complete, and the actuarial event-free survival was 58% in 44 treatment-naive SAA patients </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with refractory SAA fared less well after high-dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> therapy; at 10 years, overall actuarial survival, response, and actuarial event-free survival rates were 62%, 48%, and 27%, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>High-dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> is highly effective therapy for severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Large randomized controlled trials will be necessary to establish how results of high-dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> compare with either bone marrow transplantation or standard immunosuppressive regimens, such as antithymocyte globulin and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> </plain></SENT>
</text></document>